Parnax Lab Limited Stock

Equities

PARNAXLAB6

INE383L01019

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:56 2024-06-14 EDT 5-day change 1st Jan Change
116.7 INR +3.30% Intraday chart for Parnax Lab Limited +25.53% +32.34%

Financials

Sales 2022 1.63B 19.52M 26.8M Sales 2023 1.68B 20.07M 27.56M Capitalization 598M 7.16M 9.83M
Net income 2022 82M 982K 1.35M Net income 2023 86M 1.03M 1.41M EV / Sales 2022 1.08 x
Net Debt 2022 647M 7.75M 10.64M Net Debt 2023 534M 6.4M 8.79M EV / Sales 2023 0.68 x
P/E ratio 2022
13.6 x
P/E ratio 2023
6.69 x
Employees 12
Yield 2022 *
-
Yield 2023
-
Free-Float 26.08%
More Fundamentals * Assessed data
Dynamic Chart
Parnax Lab Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Parnax Lab Limited Approves Reconstitution of Committees of Board of Directors CI
Parnax Lab Limited Announces Retirement of Vinayak Desai as an Independent Director CI
Parnax Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Parnax Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Parnax Lab Limited Appoints Harish S. Panpalia as a Non-Executive Independent Director CI
Parnax Lab Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Parnax Lab Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Parnax Lab Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Parnax Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Parnax Lab Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Parnax Lab Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Parnax Lab Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Parnax Lab Board Allots Over 2 Million Convertible Warrants to Promoters MT
Parnax Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
More news
1 day+3.30%
1 week+25.53%
Current month+19.78%
1 month+1.32%
3 months+3.01%
6 months+33.84%
Current year+32.34%
More quotes
1 week
90.20
Extreme 90.2
118.58
1 month
89.50
Extreme 89.5
119.50
Current year
81.00
Extreme 81
167.90
1 year
55.00
Extreme 55
167.90
3 years
21.00
Extreme 21
169.90
5 years
11.65
Extreme 11.65
169.90
10 years
11.65
Extreme 11.65
169.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 80 10-12-06
Director of Finance/CFO 69 10-12-06
Compliance Officer - 21-06-20
Members of the board TitleAgeSince
Director/Board Member 83 10-07-31
Chief Executive Officer 80 10-12-06
Director of Finance/CFO 69 10-12-06
More insiders
Date Price Change Volume
24-06-14 116.7 +3.30% 44,622
24-06-13 112.9 +4.99% 3,984
24-06-12 107.6 +5.00% 4,717
24-06-11 102.4 +4.99% 11,665
24-06-10 97.58 +4.99% 10,340

Delayed Quote Bombay S.E., June 14, 2024 at 06:00 am

More quotes
Parnax Lab Limited is an India-based holding company. The Company is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations. It is also focused on the trading of pharmaceuticals and medicinal products. The Company operates through dealing in the pharmaceutical formulations segment. It is engaged in developing and delivering huge volumes of oral formulations, such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, special formulations for geriatrics, highly viscous products, suspensions and others. The Company’s subsidiary is Naxpar Pharma Private Limited.
More about the company
  1. Stock Market
  2. Equities
  3. PARNAXLAB6 Stock